Fidelio acquires Indical Bioscience

April 5, 2018

Fidelio acquires Indical Bioscience, a leading provider of diagnostic products specifically developed for veterinary specific applications.

The company develops and markets diagnostic solutions and products based on PCR (molecular) and ELISA (immunodiagnostic) technology. The products are used by laboratories primarily to indicate and diagnose viruses and bacteria in production animals, to counteract proliferation and contribute to better animal and human health.

Indical Bioscience is based in Germany and serves customers in 169 countries through its own sales force and commercial partners. Fidelio Capital acquired Indical Bioscience through a carve-out from Qiagen, a molecular diagnostic group listed on the NYSE and Frankfurt stock exchanges.

Recent news

Fidelio becomes the new majority owner of Hemfrid…

Fidelio is excited about partnering with founder Monica Lindstedt, CEO Cecilia Tosting and the entire Hemfrid team on their continued growth journey. Since its foundation in 1996, Hemfrid has been a pioneer in an industry that makes everyday life easier.

Read more

First day of trading in Vimian’s shares on …

Vimian Group AB (publ) (“Vimian”, the “Group” or the “Company”), a global, fast-growing and innovation-driven animal health business, offering products, services and solutions to veterinary professionals, labs and pet parents around the world, today announces the listing of and commencement

Read more

Vimian announces intention to list on Nasdaq Firs…

Vimian Group AB (publ), a global, fast-growing and innovation-driven animal health business, offering products, services and solutions to veterinary professionals, labs and pet parents around the world, announces its intention to carry out a private placement of shares in the

Read more